Literature DB >> 4073480

Radioimmunoassay for human type VI collagen and its application to tissue and body fluids.

D Schuppan, T Rühlmann, E G Hahn.   

Abstract

A liquid phase radioimmunoassay (RIA) was developed for pepsin-solubilized human type VI collagen, allowing quantitative analysis of this protein down to a concentration of 3 ng/ml. No cross-reactivity was observed with human collagens type I, III, IV (triple helical portion and 7-S domain), and V, nor with laminin fragment Pl and plasma fibronectin. Significant amounts of closely related antigenic material were detected in serum, bile, ascites, and mesenchymal cell culture media. Type VI collagen could be completely solubilized from several tissues by a repeated pepsin digest, and its content as determined by RIA was found to be less than 0.1% of total collagen (55-70 micrograms/g protein). In fibrotic liver tissue type VI collagen was elevated up to 10-fold (620 micrograms/g protein) when compared to normal liver. Sera of patients with fibrotic liver disease, however, revealed antigen levels usually below the narrow normal range of 22 +/- 7.8 ng/ml (mean +/- 2.5 SD). We conclude that, although type VI collagen represents a minor fraction of the interstitial collagens, its comparatively high serum levels point to a considerable turnover in the normal individual. Our data suggest that in fibrosis as exemplified in fibrotic liver disease, the metabolism of this collagen is down-regulated, while at the same time, it accumulates in the interstitial matrix.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4073480     DOI: 10.1016/0003-2697(85)90501-9

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  22 in total

1.  Immunoelectron microscopy shows an atypical pattern and a quantitative shift of collagens type I, III and VI in oral Kaposi's sarcoma of AIDS.

Authors:  J Becker; D Schuppan; J P Rabanus; H R Gelderblom; P Reichart
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Type VI collagen in experimental atherosclerosis.

Authors:  R Kittelberger; P F Davis; W E Stehbens
Journal:  Experientia       Date:  1990-03-15

3.  Type II collagen serology: a guide to clinical responsiveness to oral tolerance?

Authors:  U Gimsa; J Sieper; J Braun; N A Mitchison
Journal:  Rheumatol Int       Date:  1997       Impact factor: 2.631

4.  Intestinal epithelial cells preferentially attach to a biomatrix derived from human intestinal mucosa.

Authors:  U Hahn; A Cho; D Schuppan; E G Hahn; H J Merker; E O Riecken
Journal:  Gut       Date:  1987       Impact factor: 23.059

5.  Intestinal cells produce basement membrane proteins in vitro.

Authors:  U Hahn; D Schuppan; E G Hahn; H J Merker; E O Riecken
Journal:  Gut       Date:  1987       Impact factor: 23.059

6.  Immunofluorescent localization of type-V collagen as a fibrillar component of the interstitial connective tissue of human oral mucosa, artery and liver.

Authors:  D Schuppan; J Becker; H Boehm; E G Hahn
Journal:  Cell Tissue Res       Date:  1986       Impact factor: 5.249

7.  Immunohistochemical investigation of collagen subtypes in human glioblastomas.

Authors:  W Paulus; W Roggendorf; D Schuppan
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

8.  Characterization of integrin receptors in normal and neoplastic human brain.

Authors:  W Paulus; I Baur; D Schuppan; W Roggendorf
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

9.  Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease.

Authors:  F Stickel; R Urbaschek; D Schuppan; G Poeschl; C Oesterling; C Conradt; R S McCuskey; U A Simanowski; H K Seitz
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

10.  Prominent collagen type VI expression in juvenile angiofibromas.

Authors:  Monika Gramann; Olaf Wendler; Lothar Haeberle; Bernhard Schick
Journal:  Histochem Cell Biol       Date:  2008-09-17       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.